Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sang T Kim

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Immunology and Allergy Clinics of North America|April 26, 2025
The Current and Future of Biomarkers of Immune Related Adverse EventsWilliam Bracamonte-Baran, Sang T Kim
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2026
Immune checkpoint inhibitor-associated inflammatory arthritisSang T Kim, Anne R Bass
Rheumatic Diseases Clinics of North America|April 26, 2024
The Current and Future of Biomarkers of Immune Related Adverse EventsWilliam Bracamonte-Baran, Sang T Kim
Expert Review of Clinical Immunology|December 28, 2018
Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologistsSang T Kim, Maria E Suarez-Almazor
Cancers|August 7, 2021
Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and ApoptosisEmma Rodriguez, Guangsheng Pei, Sang T Kim, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate CancerSang T Kim, William A Murphy, Ana Aparicio, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 14, 2017
Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of CancerMaria E Suarez-Almazor, Sang T Kim, Noha Abdel-Wahab, et al.
Cancers|October 23, 2021
Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. <i>Cancers</i> 2021, <i>13</i>, 3871Emma Rodriguez, Guangsheng Pei, Zhongming Zhao, et al.
Current Alzheimer Research|September 13, 2018
Mapping Exchangeable Protons to Monitor Protein Alterations in the Brain of an Alzheimer's Disease Mouse Model by Using MRIGeon-Ho Jahng, Wonmin Choi, Julius J Chung, et al.
AACE Clinical Case Reports|June 12, 2020
A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMASara Bedrose, Christie G Turin, Victor R Lavis, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Immunology and Allergy Clinics of North America|April 26, 2025
The Current and Future of Biomarkers of Immune Related Adverse EventsWilliam Bracamonte-Baran, Sang T Kim
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2026
Immune checkpoint inhibitor-associated inflammatory arthritisSang T Kim, Anne R Bass
Rheumatic Diseases Clinics of North America|April 26, 2024
The Current and Future of Biomarkers of Immune Related Adverse EventsWilliam Bracamonte-Baran, Sang T Kim
Expert Review of Clinical Immunology|December 28, 2018
Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologistsSang T Kim, Maria E Suarez-Almazor
Cancers|August 7, 2021
Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and ApoptosisEmma Rodriguez, Guangsheng Pei, Sang T Kim, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate CancerSang T Kim, William A Murphy, Ana Aparicio, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 14, 2017
Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of CancerMaria E Suarez-Almazor, Sang T Kim, Noha Abdel-Wahab, et al.
Cancers|October 23, 2021
Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. <i>Cancers</i> 2021, <i>13</i>, 3871Emma Rodriguez, Guangsheng Pei, Zhongming Zhao, et al.
Current Alzheimer Research|September 13, 2018
Mapping Exchangeable Protons to Monitor Protein Alterations in the Brain of an Alzheimer's Disease Mouse Model by Using MRIGeon-Ho Jahng, Wonmin Choi, Julius J Chung, et al.
AACE Clinical Case Reports|June 12, 2020
A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMASara Bedrose, Christie G Turin, Victor R Lavis, et al.
Pageof 3